Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

MediWound Ltd. Proxy Solicitation & Information Statement 2022

Oct 21, 2022

33721_ffr_2022-10-21_8ffaf4c8-7406-4967-a0e1-318d6cd0d184.zip

Proxy Solicitation & Information Statement

Open in viewer

Opens in your device viewer

6-K 1 zk2228578.htm 6-K Licensed to: Z-K GLOBAL Document created using Broadridge PROfile 22.10.1.5080 Copyright 1995 - 2022 Broadridge

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 ____

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

For the month of October 2022

Commission File Number: 001-36349

MediWound Ltd. (Translation of registrant’s name into English

42 Hayarkon Street

Yavne, 8122745 Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): __

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): __

CONTENTS

Annexed hereto and incorporated herein by reference are copies of the following items being furnished by MediWound Ltd. (the “ Company ”):

  1. Notice of Extraordinary General Meeting of the Company’s Shareholders and Proxy Statement, each dated October 21, 2022, to be mailed to the shareholders of the Company in connection with the Extraordinary General Meeting of the Company’s Shareholders, which is scheduled to be held on November 28, 2022 (the “ Meeting ”), annexed as Exhibit 99.1 hereto.

  2. Proxy Card to be mailed to holders of the ordinary shares of the Company for use in connection with the Meeting, annexed as Exhibit 99.2 hereto.

The contents of this Report of Foreign Private Issuer on Form 6-K (this “ Form 6-K ”) (including Exhibits 99.1 and 99.2) are hereby incorporated by reference into the Company’s Registration Statements on Form S-8 filed with the SEC on April 28, 2014, March 24, 2016, March 19, 2018, March 25, 2019, February 25, 2020 and May 15, 2021 (Registration Nos. No. 333-195517, 333-210375, 333-223767, 333-195517, 333-210375, 333-230487, 333-236635 and 333-255784, respectively) and on Form F-3 filed with the SEC on May 25, 2022 (Registration No. 333-265203).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: October 21, 2022 MEDIWOUND LTD. By: /s/ Boaz Gur-Lavie Name: Boaz Gur-Lavie Title: Chief Financial Officer

EXHIBIT INDEX

The following exhibits are furnished as part of this Form 6-K:

Exhibit Description
99.1 Notice of Extraordinary General Meeting and Proxy
Statement, each dated October 21, 2022, in connection with the Extraordinary General Meeting of Shareholders of the Company scheduled to be held on November 28, 2022.
99.2 Proxy Card to be mailed to holders of the ordinary shares
of the Company for use in connection with the Extraordinary General Meeting of Shareholders of the Company scheduled to be held on November 28, 2022.